Calquence combo approved by FDA for untreated mantle cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Calquence (acalabrutinib) as a treatment for mantle cell lymphoma (MCL), a rare and…
Discrepancies were identified between two genetic analysis platforms used to detect mutations that guide the treatment of ovarian, fallopian tube, or primary peritoneal cancers in…
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…
Authorities in Germany have given Oncolytics Biotech the go-ahead to continue enrollment in a Phase 1/2 clinical trial testing the company’s viral therapy pelareorep…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to a novel brain cancer treatment — one designed for malignant gliomas…
An expansion of Medicaid services in the state of Virginia led within months to more young and middle-aged women of lower income being treated in…
A subcutaneous, or under-the-skin, formulation of Sarclisa (isatuximab) is just as effective as the approved intravenous (into-the-vein) version of the therapy at controlling treatment-resistant…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Puretech Health’s LYT-200, an investigative treatment for acute myeloid leukemia…
Investigational oral therapy IMM-1-104 was well tolerated and showed early signs of efficacy as a first- or second-line treatment for pancreatic cancer. That’s according…
Brainchild Bio plans to launch a pivotal Phase 2 clinical trial to test its investigational cell therapy BCB-276 in patients with diffuse intrinsic pontine…